CA1146859A - Pharmaceutical preparations containing zinc - Google Patents
Pharmaceutical preparations containing zincInfo
- Publication number
- CA1146859A CA1146859A CA000340999A CA340999A CA1146859A CA 1146859 A CA1146859 A CA 1146859A CA 000340999 A CA000340999 A CA 000340999A CA 340999 A CA340999 A CA 340999A CA 1146859 A CA1146859 A CA 1146859A
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical preparation
- preparation according
- acceptable salt
- pharmaceutically acceptable
- zinc ions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title claims abstract description 27
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title claims abstract description 8
- 229910052725 zinc Inorganic materials 0.000 title claims abstract description 8
- 239000011701 zinc Substances 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 39
- 239000002253 acid Substances 0.000 claims abstract description 30
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000000499 gel Substances 0.000 claims abstract description 17
- 150000004676 glycans Chemical class 0.000 claims abstract description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims abstract description 14
- 239000005017 polysaccharide Substances 0.000 claims abstract description 14
- 229920000642 polymer Polymers 0.000 claims abstract description 12
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 12
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims abstract description 11
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims abstract description 9
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims abstract description 9
- 230000000840 anti-viral effect Effects 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 6
- 239000006071 cream Substances 0.000 claims abstract description 5
- 239000002674 ointment Substances 0.000 claims abstract description 5
- 229920000669 heparin Polymers 0.000 claims description 25
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 23
- 229960002897 heparin Drugs 0.000 claims description 23
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 18
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 17
- 159000000000 sodium salts Chemical class 0.000 claims description 14
- 229920002307 Dextran Polymers 0.000 claims description 13
- 229920000053 polysorbate 80 Polymers 0.000 claims description 11
- 229920002554 vinyl polymer Polymers 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 5
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- RZLVQBNCHSJZPX-UHFFFAOYSA-L zinc sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Zn+2].[O-]S([O-])(=O)=O RZLVQBNCHSJZPX-UHFFFAOYSA-L 0.000 claims description 3
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 150000003752 zinc compounds Chemical class 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229940098465 tincture Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 18
- -1 tinctures Substances 0.000 abstract description 17
- 208000001688 Herpes Genitalis Diseases 0.000 abstract description 5
- 201000004946 genital herpes Diseases 0.000 abstract description 5
- 238000011200 topical administration Methods 0.000 abstract description 4
- 241001529453 unidentified herpesvirus Species 0.000 abstract description 4
- 206010062639 Herpes dermatitis Diseases 0.000 abstract description 3
- 239000003443 antiviral agent Substances 0.000 abstract 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 11
- 239000011686 zinc sulphate Substances 0.000 description 11
- 235000009529 zinc sulphate Nutrition 0.000 description 11
- OHJKXVLJWUPWQG-PNRHKHKDSA-N Heparinsodiumsalt Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](O)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O)[C@H](C(O)=O)O1 OHJKXVLJWUPWQG-PNRHKHKDSA-N 0.000 description 10
- 241000700605 Viruses Species 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 235000014113 dietary fatty acids Nutrition 0.000 description 9
- 239000000194 fatty acid Substances 0.000 description 9
- 229930195729 fatty acid Natural products 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 229920001214 Polysorbate 60 Polymers 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 241000287828 Gallus gallus Species 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 210000001161 mammalian embryo Anatomy 0.000 description 6
- 102100027085 Dual specificity protein phosphatase 4 Human genes 0.000 description 5
- 101001057621 Homo sapiens Dual specificity protein phosphatase 4 Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- BXWNKGSJHAJOGX-UHFFFAOYSA-N n-hexadecyl alcohol Natural products CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 150000005846 sugar alcohols Polymers 0.000 description 5
- 230000002195 synergetic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 239000003995 emulsifying agent Substances 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 4
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 4
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 4
- 229920001817 Agar Polymers 0.000 description 3
- 239000004166 Lanolin Substances 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 229960000541 cetyl alcohol Drugs 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 235000019271 petrolatum Nutrition 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000007505 plaque formation Effects 0.000 description 3
- 229940100515 sorbitan Drugs 0.000 description 3
- 150000003751 zinc Chemical class 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000004898 Herpes Labialis Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 229920000715 Mucilage Polymers 0.000 description 2
- 206010067152 Oral herpes Diseases 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 230000001741 anti-phlogistic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N n-hexadecanoic acid Natural products CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- SYCHUQUJURZQMO-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-n-(1,3-thiazol-2-yl)-1$l^{6},2-benzothiazine-3-carboxamide Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=CS1 SYCHUQUJURZQMO-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical class C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 102000004407 Lactalbumin Human genes 0.000 description 1
- 108090000942 Lactalbumin Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QOSMNYMQXIVWKY-UHFFFAOYSA-N Propyl levulinate Chemical compound CCCOC(=O)CCC(C)=O QOSMNYMQXIVWKY-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- FGUZFFWTBWJBIL-XWVZOOPGSA-N [(1r)-1-[(2s,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)O[C@H](CO)[C@H]1OC[C@H](O)[C@H]1O FGUZFFWTBWJBIL-XWVZOOPGSA-N 0.000 description 1
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920003086 cellulose ether Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960003469 flumetasone Drugs 0.000 description 1
- WXURHACBFYSXBI-GQKYHHCASA-N flumethasone Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]2(C)C[C@@H]1O WXURHACBFYSXBI-GQKYHHCASA-N 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 150000002731 mercury compounds Chemical class 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- HBDHXDBPCVDGQN-FPLPWBNLSA-N propan-2-yl (z)-tetradec-9-enoate Chemical compound CCCC\C=C/CCCCCCCC(=O)OC(C)C HBDHXDBPCVDGQN-FPLPWBNLSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 description 1
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229940057429 sorbitan isostearate Drugs 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 229950005175 sudoxicam Drugs 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000004246 zinc acetate Substances 0.000 description 1
- 235000013904 zinc acetate Nutrition 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 239000011746 zinc citrate Substances 0.000 description 1
- 235000006076 zinc citrate Nutrition 0.000 description 1
- 229940068475 zinc citrate Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH12360/78-6 | 1978-12-04 | ||
| CH1236078 | 1978-12-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1146859A true CA1146859A (en) | 1983-05-24 |
Family
ID=4382297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000340999A Expired CA1146859A (en) | 1978-12-04 | 1979-11-30 | Pharmaceutical preparations containing zinc |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0012115A1 (enExample) |
| JP (1) | JPS5579321A (enExample) |
| AU (1) | AU531882B2 (enExample) |
| CA (1) | CA1146859A (enExample) |
| IT (1) | IT1164070B (enExample) |
| LU (1) | LU81944A1 (enExample) |
| NZ (1) | NZ192294A (enExample) |
| SE (1) | SE448604B (enExample) |
| ZA (1) | ZA796549B (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840941A (en) * | 1986-04-04 | 1989-06-20 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Method for inhibiting infection of human T-cells |
| US5100879A (en) * | 1987-03-31 | 1992-03-31 | K.K. Ueno Seiyaku Oyo Kenkyujo | Method of topically cleansing the human body |
| US5624675A (en) * | 1989-06-06 | 1997-04-29 | Kelly; Patrick D. | Genital lubricants containing zinc salts to reduce risk of HIV infection |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2080682B (en) * | 1980-07-30 | 1984-03-28 | Ciba Geigy Ag | Antiherpetically active lipstick |
| DE3273138D1 (en) * | 1981-06-02 | 1986-10-16 | Eupan Corp | Eustatic composition for nonspecifically facilitating and amplifying the generalized homeostatic regulation and maintenance, compensation and repair in living organisms |
| AU556817B2 (en) * | 1982-02-03 | 1986-11-20 | Efamol Limited | Topical application of a lithium salt and dihomo-alpha- linolenic acid |
| FR2548023B1 (fr) * | 1983-06-16 | 1987-06-26 | Victoria State | Medicament veterinaire et solution de bain de pieds pour le traitement du pietin des ovins |
| US4661354A (en) * | 1984-06-21 | 1987-04-28 | Finnerty Edmund F | Topical treatment of herpes simplex with a zinc sulfate-camphor water solution |
| US4895727A (en) * | 1985-05-03 | 1990-01-23 | Chemex Pharmaceuticals, Inc. | Pharmaceutical vehicles for exhancing penetration and retention in the skin |
| WO1988007060A1 (en) * | 1987-03-19 | 1988-09-22 | Arthropharm Pty. Limited | Anti-inflammatory compounds and compositions |
| AU620218B2 (en) * | 1989-02-10 | 1992-02-13 | Taiho Pharmaceutical Co., Ltd. | Anti-hiv drug |
| EP0402078A3 (en) * | 1989-06-06 | 1991-07-31 | Patrick Daniel Kelly | Sexual lubricants containing zinc as an anti-viral agent |
| DE4200499A1 (de) * | 1992-01-10 | 1993-07-15 | Bode Chemie Gmbh & Co | Desinfektionsmittel |
| JP2571190Y2 (ja) * | 1992-10-31 | 1998-05-13 | 株式会社ミヨシ | パワーショベル等の油圧回路 |
| GB9521805D0 (en) * | 1995-10-25 | 1996-01-03 | Cortecs Ltd | Solubilisation methods |
| US6475526B1 (en) * | 2001-06-05 | 2002-11-05 | Jeffrey B. Smith | Zinc containing compositions for anti-viral use |
| US7968122B2 (en) | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
| EP2283805A1 (en) | 2009-07-28 | 2011-02-16 | Sirvis BV | Compositions comprising a zinc containing compound dissolved in a hydrophobic phase |
| JP6139506B2 (ja) * | 2011-04-04 | 2017-05-31 | コロプラスト アクティーゼルスカブ | 接着パッチ |
| EP3791884A1 (en) | 2019-09-16 | 2021-03-17 | Oskar Bunz | Combination of heparin and magnesium salt for the treatment of viral infections |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU77562A1 (de) * | 1977-06-17 | 1979-03-26 | Ciba Geigy Ag | Verfahren zur herstellung von neuen pharmazeutischen praeparaten |
| JPS6225126A (ja) * | 1985-07-25 | 1987-02-03 | Matsushita Electric Works Ltd | 付加型イミド樹脂積層板 |
-
1979
- 1979-11-28 EP EP79810167A patent/EP0012115A1/de not_active Withdrawn
- 1979-11-30 IT IT50953/79A patent/IT1164070B/it active
- 1979-11-30 CA CA000340999A patent/CA1146859A/en not_active Expired
- 1979-12-03 AU AU53379/79A patent/AU531882B2/en not_active Ceased
- 1979-12-03 ZA ZA00796549A patent/ZA796549B/xx unknown
- 1979-12-03 SE SE7909952A patent/SE448604B/sv not_active IP Right Cessation
- 1979-12-03 LU LU81944A patent/LU81944A1/de unknown
- 1979-12-03 NZ NZ192294A patent/NZ192294A/xx unknown
- 1979-12-04 JP JP15645879A patent/JPS5579321A/ja active Granted
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4840941A (en) * | 1986-04-04 | 1989-06-20 | Kabushiki Kaisha Ueno Seiyaku Oyo Kenkyujo | Method for inhibiting infection of human T-cells |
| US5100879A (en) * | 1987-03-31 | 1992-03-31 | K.K. Ueno Seiyaku Oyo Kenkyujo | Method of topically cleansing the human body |
| US5624675A (en) * | 1989-06-06 | 1997-04-29 | Kelly; Patrick D. | Genital lubricants containing zinc salts to reduce risk of HIV infection |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA796549B (en) | 1980-11-26 |
| AU5337979A (en) | 1980-06-12 |
| LU81944A1 (de) | 1980-07-01 |
| IT1164070B (it) | 1987-04-08 |
| JPS5579321A (en) | 1980-06-14 |
| NZ192294A (en) | 1982-05-31 |
| EP0012115A1 (de) | 1980-06-11 |
| SE448604B (sv) | 1987-03-09 |
| JPS6348849B2 (enExample) | 1988-09-30 |
| SE7909952L (sv) | 1980-06-05 |
| IT7950953A0 (it) | 1979-11-30 |
| AU531882B2 (en) | 1983-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1146859A (en) | Pharmaceutical preparations containing zinc | |
| US4465666A (en) | New pharmaceutical preparations | |
| KR0128287B1 (ko) | 맥관형성 치료 및 예방용 약제학적 제제 | |
| CA1050548A (en) | Zinc sulfadiazine as a medicament | |
| CA2310207C (en) | Topical zinc compositions and methods of use | |
| CA1199273A (en) | Anti-inflammatory composition | |
| DE69615184T2 (de) | Fungizid | |
| US4607038A (en) | Ophthalmic pranoprofen compositions | |
| US4797392A (en) | Use of anorectal compositions | |
| US5086075A (en) | Therapeutic compositions containing benzoyl peroxide | |
| US6348190B1 (en) | Pharmaceutical compositions with antimicrobial activity | |
| DE2709121C2 (enExample) | ||
| EP1115408B1 (en) | Oxihumic acid and its use in the treatment of various conditions | |
| US4034114A (en) | Treatment of skin keratoses with retinal | |
| EP1858531A1 (en) | Use of copper silicate for the control of herpes infections | |
| KR910002442A (ko) | 안구질환을 치료하는 방법 및 제약학적 조성물 | |
| JP2004035411A (ja) | 外用抗真菌剤 | |
| US5008255A (en) | Method for enhancing solubility of trimethoprim with sodium sulfacetamide, and synergistic pharmaceutical compositions derived therefrom | |
| Cafruny | 524 Histochemical demonstration of mercury in renal cells | |
| Sawyer et al. | 523 Antidiuretic responses to neurohypophysial hormones and some of their synthetic analogues in dogs and rats | |
| Vahlensieck | Pharmakologische Prophylaxe und Therapie von Blutungen im ableitenden Harntrakt | |
| Peters et al. | 526 Influence of a nephrotoxic agent on the renal concentrating mechanism in the rat | |
| DE4124695A1 (de) | Carbacyclinderivate als mittel zur behandlung von psoriasis vulgaris | |
| Vasodilator | Acetylsalicylic acid. | |
| DE4139733A1 (de) | Carbacyclinderivate als mittel zur behandlung von krankheitsbildern, die zum atopie-kreis gehoeren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |